Story

Immatics Stock Rises on $150 Million Offering and Goldman Sachs Buy Rating

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20261 min read
Immatics Stock Rises on $150 Million Offering and Goldman Sachs Buy Rating
Text size
Background

Shares of Immatics NV (IMTX) rose nearly 4.7% to $9.10 in pre-open trading on Tuesday, driven by a new capital raise and a positive analyst endorsement.

Capital Raise and Analyst Confidence

Immatics announced plans for a $150 million underwritten public offering. The company intends to sell 12,945,916 shares at a price of $8.69 each, according to a company announcement.

In addition to the shares, the offering includes 4,315,304 pre-funded warrants priced at the same level. The news was followed by an endorsement from Goldman Sachs, which reiterated its Buy rating on the stock just hours after Immatics released its second-quarter 2026 interim financial results.

Market Outlook

Sample IUX Markets – In-articleAd

The move by Goldman Sachs adds to a broadly bullish analyst view on the biotechnology firm. According to market data cited by Investing.com, Immatics holds a Strong Buy consensus rating among analysts.

Key points on the analyst outlook include:

  • An average 12-month price target in the range of $17–$19.
  • This target suggests more than double the potential upside from Tuesday's pre-market price.

Investor sentiment was also supported by a broader rise in the NASDAQ Composite, providing a favorable environment for growth-oriented stocks. Despite the recent gains, the stock remains below its 52-week high of $12.41.

Read next

More on Stocks
Back to latest news

LATEST